Browse by Administration Route

This page shows data for Intradermal virus.
Total Entries Retrieved: 12
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10065 ZyCoV-D COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Approved Zydus Candila Healthcare Limited 2021 India 12 years and above NA Intradermal NA SARS CoV-2 envelope protein NA DCGI NA India NA NA NA https://pib.gov.in/PressReleasePage.aspx?PRID=1747669#:~:text=Zydus%20Cadila%20has%20received%20approval,adults%2012%20years%20and%20above. NA
10167 CORVax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Providence Health & Services NA NA NA 2 doses 14 days apart Intradermal NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10193 CORVax12 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Providence Health & Services, OncoSec Medical Inc. 2021 USA 18 years and above NA Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT04627675 https://clinicaltrials.gov/ct2/show/NCT04627675 NA
10248 EXG-5003 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Elixirgen Therapeutics Inc. 2021 Japan 20 - 55 years NA Intradermal NA NA mRNA based vaccine NA NA NA NA NA NCT04863131 https://clinicaltrials.gov/show/NCT04863131 NA
10253 ZyCoV-D COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Cadila Healthcare Ltd NA NA NA 3 doses on day 0, 28 and 56 Intradermal NA NA NA NA NA NA nCov vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10282 GLS-5310 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 GeneOne Life Science Inc. 2021 South Korea 19 - 65 years 2 doses 28 days apart Intradermal NA NA NA NA NA NA NA NA NCT04673149 https://clinicaltrials.gov/show/NCT04673149 NA
10293 GLS-5300 (INO-4700) MERS Respiratory MERS-CoV positive-sense, single-stranded RNA DNA based vaccine Phase 2 GeneOne Life Science Inc. 2020 South Korea 19 - 70 years 3 doses Intradermal NA MERS CoV spike glycoprotein NA NA Inovio Pharmaceuticals, International Vaccine Institute NA GLS-5300 NA NCT03721718 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ NA
10324 INO-4800 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Inovio Pharmaceuticals 2021 USA 18 years and above 2 doses 28 days apart Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Further-Expands-INNOVATE-Phase-3-Trial-for-COVID-19-DNA-Vaccine-Candidate-INO-4800-With-Regulatory-Authorization-from-India/default.aspx
10325 INO-4800 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 Inovio Pharmaceuticals 2021 USA 18 years and above 2 doses 28 days apart Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.isrctn.com/ISRCTN15779782
10398 DREP-Env Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA Intradermal NA CHIKV replicon (nsP1 to nsP4) and CHIKV envelope proteins (E1, E2, and E3) NA NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10418 DREP-Env Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Preclinical NA NA NA NA NA Intradermal NA DNA replicon encoding nsP and E1, E2, E3 NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA